E
VERV

Ergoteles’s Verve Therapeutics VERV Stock Holding History

Ergoteles’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-74,000
Closed -$1.13M – 2009
2022
Q2 		$1.13M Buy
+74,000
New +$1.15M 0.03% 499
2022
Q1 		– Sell
-26,267
Closed -$968K – 1649
2021
Q4 		$968K Buy
+26,267
New +$1.1M 0.04% 424

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ergoteles's VERV Position: Q3 2022 in Review

Ergoteles sold out of Verve Therapeutics (VERV) in Q3 2022, closing a stake of 74,000 shares — an estimated $1.13M sold.

Ergoteles first reported a position in VERV in Q4 2021 and held it in 2 quarters. The position peaked at $1.13M in Q2 2022. 125 funds tracked by Wall St. Rank hold VERV as of Q3 2022.

  • Ergoteles reported no remaining Verve Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 74,000 Verve Therapeutics shares in Q3 2022, an estimated $1.13M.
  • Ergoteles first reported a position in Verve Therapeutics in Q4 2021 and held it in 2 quarters.
  • Ergoteles's Verve Therapeutics position peaked at $1.13M in Q2 2022.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.